The Advaxis Inc. (ADXS) to Post FY2016 Earnings of ($2.13) Per Share, The Zacks Investment Research Forecasts

The Advaxis Inc. (ADXS) to Post FY2016 Earnings of ($2.13) Per Share, The Zacks Investment Research Forecasts

Advaxis Inc. (NASDAQ:ADXS) – Investment analysts at Zacks Investment Research upped their FY2016 EPS estimates for Advaxis in a research report issued on Tuesday. Zacks Investment Research analyst G. Zeng now forecasts that the brokerage will post earnings of ($2.13) per share for the year, up from their prior estimate of ($2.26). Zacks Investment Research also issued estimates for Advaxis’ FY2017 earnings at ($2.48) EPS, FY2018 earnings at ($1.33) EPS and FY2019 earnings at ($0.18) EPS.

A number of other equities analysts also recently issued reports on the company. HC Wainwright set a $23.00 price target on Advaxis and gave the stock a “buy” rating in a research report on Tuesday, October 25th. Jefferies Group reaffirmed a “buy” rating and set a $24.00 price target on shares of Advaxis in a research report on Friday, September 9th. Barclays PLC upped their price target on Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 3rd. Finally, FBR & Co reaffirmed an “outperform” rating and set a $34.00 price target on shares of Advaxis in a research report on Thursday, July 7th. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $24.60.

Shares of Advaxis (NASDAQ:ADXS) opened at 8.02 on Friday. The firm’s 50-day moving average price is $10.11 and its 200-day moving average price is $9.70. The company’s market capitalization is $319.55 million. Advaxis has a 12-month low of $5.21 and a 12-month high of $16.30.

Institutional investors have recently added to or reduced their stakes in the stock. Pictet Asset Management Ltd. increased its position in Advaxis by 742.8% in the second quarter. Pictet Asset Management Ltd. now owns 1,428,619 shares of the biotechnology company’s stock valued at $13,229,000 after buying an additional 1,259,119 shares during the last quarter. Vanguard Group Inc. increased its position in Advaxis by 6.1% in the second quarter. Vanguard Group Inc. now owns 1,326,913 shares of the biotechnology company’s stock valued at $10,735,000 after buying an additional 75,731 shares during the last quarter. BlackRock Fund Advisors increased its position in Advaxis by 10.0% in the second quarter. BlackRock Fund Advisors now owns 869,989 shares of the biotechnology company’s stock valued at $7,038,000 after buying an additional 79,385 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Advaxis by 2.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 728,300 shares of the biotechnology company’s stock valued at $5,892,000 after buying an additional 14,689 shares during the last quarter. Finally, Sarissa Capital Management LP purchased a new position in Advaxis during the second quarter valued at about $4,853,000. 55.44% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Richard J. Berman sold 18,000 shares of the company’s stock in a transaction on Monday, August 8th. The stock was sold at an average price of $15.21, for a total value of $273,780.00. Following the transaction, the director now directly owns 66,430 shares of the company’s stock, valued at approximately $1,010,400.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David Sidransky sold 22,808 shares of the company’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $15.01, for a total value of $342,348.08. Following the completion of the transaction, the director now directly owns 91,759 shares in the company, valued at $1,377,302.59. The disclosure for this sale can be found here. 4.56% of the stock is owned by corporate insiders.

About Advaxis

Related posts

Leave a Comment